IMPORTANCE OF THE SPINE MAPPING SYSTEM IN ANKYLOSING SPONDILITIS
Abstract
Ankylosing spondylitis (AS) is an autoimmune autoinflammatory disease with inflammatory processes of the spine and sacroiliac joints. Radiographic examinations are one of the main tools in diagnosing AS and assessing the dynamics of disease development. Correct and systematic visualization examinations allow to identify structural changes in the sacroiliitis and spine even in the early stages of the disease. This article reviews the use of radiographic techniques, including computed tomography (CT) and magnetic resonance imaging (MRI), in the diagnosis of AS. The article also analyzes the importance of evaluating the disease through the mapping system of sacroiliac joint and spinal injuries. The mapping system allows for a complete understanding of structural changes and their step-by-step tracking.
References
1. Abdurakhmanova, N., Akhmedov, K., Jabbarov, O., Rakhimova, M., Tagaeva, M., Khalmetova, F., & Tursunova, L. (2022). Clinical And Diagnostic Significance Of Anti-Cd74 In Patients With Ankylosing Spondylitis Of Uzbek Population.
2. Arévalo M, Gratacós Masmitjà J, Moreno M, et al. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: Results from the REGISPONSER database. Arthritis Research and Therapy. 2018;20(1). doi:10.1186/s13075-018-1724-7
3. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570). doi:10.1016/S0140-6736(07)60635-7
4. Buranova S.N. Method of treatment aimed at the dynamics of cartilage oligomer matrix protein (COMP) in patients with osteoarthritis. // Turkish Journal of Physiotherapy and Rehabilitation; №32 (2) -P.4039-4041.
5. Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). Molecular Medicine Reports. 2017;15(4). doi:10.3892/mmr.2017.6248
6. Danve A, O’Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. International Journal of Rheumatic Diseases. 2015;18(8). doi:10.1111/1756-185X.12779
7. Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: What, when and how? Rheumatology (United Kingdom). 2020;59. doi:10.1093/rheumatology/keaa435
8. Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: Understanding the disease and management. F1000Research. 2018;7. doi:10.12688/F1000RESEARCH.14956.1
9. Garcia-Montoya L, Marzo-Ortega H. The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Therapeutic Advances in Musculoskeletal Disease. 2018;10(9). doi:10.1177/1759720X18787766
10. Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clinical Rheumatology. 2021;40(8). doi:10.1007/s10067-021-05679-7
11. Klingberg E, Strid H, Ståhl A, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Research and Therapy. 2017;19(1). doi:10.1186/s13075-017-1223-2
12. Ogdie A, de Vlam K, McInnes IB, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6(1). doi:10.1136/rmdopen-2019-001042
13. Ossum AM, Palm Ø, Lunder AK, et al. Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: Results from 20 years of follow-up in the IBSEN study. Journal of Crohn’s and Colitis. 2018;12(1). doi:10.1093/ecco-jcc/jjx126
14. Prof F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Therapeutic Advances in Musculoskeletal Disease. 2018;10(5-6). doi:10.1177/1759720X18773726
15. Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. Journal of Autoimmunity. 2014;48-49. doi:10.1016/j.jaut.2014.01.015
16. Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Molecular Immunology. 2014;57(1). doi:10.1016/j.molimm.2013.06.013
17. Van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases. 2022;81(11). doi:10.1136/ard-2022-222608
18. Van der Heijde D, Braun J, Deodhar A, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (United Kingdom). 2019;58(3). doi:10.1093/rheumatology/key128
19. Wang C, Liao Q, Hu Y, Zhong D. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Experimental and Therapeutic Medicine. 2015;9(1). doi:10.3892/etm.2014.2046
20. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: An update. Current Opinion in Rheumatology. 2018;30(2). doi:10.1097/BOR.0000000000000475
21. Wen C, Zheng Z, Shao T, et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. Genome Biology. 2017;18(1). doi:10.1186/s13059-017-1271-6
22. Xalmetova, F. I., X. S. Akhmedov, and S. N. Buranova. "The Role of Imaging Techniques in the Assessment of Structural Changes in the Joint in Reactive Arthritis." Academicia Globe: Inderscience Research 3.03 (2022): 186-189.
23. Xi Y, Jiang T, Chaurasiya B, et al. Advances in nanomedicine for the treatment of ankylosing spondylitis. International Journal of Nanomedicine. 2019;14. doi:10.2147/IJN.S216199
24. Yin Y, Wang M, Liu M, et al. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Arthritis Research and Therapy. 2020;22(1). doi:10.1186/s13075-020-02208-w
25. Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Research. 2019;7(1). doi:10.1038/s41413-019-0057-8
